Form 8-K - Current report:
SEC Accession No. 0001558370-22-014609
Filing Date
2022-09-26
Accepted
2022-09-26 08:30:20
Documents
12
Period of Report
2022-09-22
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K sgtx-20220922x8k.htm   iXBRL 8-K 34381
  Complete submission text file 0001558370-22-014609.txt   156412

Data Files

Seq Description Document Type Size
2 EX-101.SCH sgtx-20220922.xsd EX-101.SCH 2951
3 EX-101.LAB sgtx-20220922_lab.xml EX-101.LAB 16579
4 EX-101.PRE sgtx-20220922_pre.xml EX-101.PRE 10453
6 EXTRACTED XBRL INSTANCE DOCUMENT sgtx-20220922x8k_htm.xml XML 5047
Mailing Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142
Business Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142 617-336-7540
Sigilon Therapeutics, Inc. (Filer) CIK: 0001821323 (see all company filings)

EIN.: 474005543 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39746 | Film No.: 221263655
SIC: 2834 Pharmaceutical Preparations